Chest coil passes Philips compatibility testing
RNS Number : 5089J
Polarean Imaging PLC
01 December 2025
Polarean Imaging Plc
("Polarean" or the "Company")
XENOVIEW® 3T coil passes Philips compatibility testing
Polarean's FDA cleared coil achieves important milestone, expanding clinical reach
Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips' latest 3T MRI platforms.
Following extensive validation by Philips, the XENOVIEW® 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in early 2026, including 3.0T platforms such as the MR 7700 and Ingenia Elition X, along with their associated upgrade pathways. Building on Philips' introduction of Xenon MRI compatibility in 2022 with the MR 7700, the addition of the Polarean XENOVIEW 3T Chest Coil expands access to advanced pulmonary imaging and supports a new era of functional lung assessment. This confirmation, building on the coil's FDA clearance in 2024, positions the technology for rapid clinical adoption and revenue generation. The XENOVIEW 3T Chest Coil enables healthcare providers to seamlessly adopt advanced functional lung ventilation imaging, supporting broader clinical adoption and advancing the Company's commitment to innovation in pulmonary imaging.
This milestone marks a major advance in scaling Polarean's Xenon MRI technology across a major global installed base and enables clinical and research sites using Philips MRI systems to incorporate non-invasive, quantitative assessments of lung function as part of routine care and research. Following this, Polarean is well positioned to accelerate adoption, expand market penetration and enhance significant commercial and clinical value worldwide.
Christopher von Jako, Ph.D., Chief Executive Officer of Polarean commented: "This milestone marks another important advancement in our vision to optimise lung health and prevent avoidable loss by illuminating hidden disease. Compatibility with Philips' state-of-the-art MRI platforms greatly broadens the accessibility of Xenon MRI and will help more hospitals and imaging centres adopt this powerful technology. Equally significant, our FDA-cleared coil's seamless integration with Philips systems positions us to drive adoption by reducing workflow complexity for clinicians, accelerating market penetration and unlocking growth opportunities."
Gwenael Herigault, Global MR Clinical Leader at Philips commented: "The compatibility of Polarean's FDA-cleared XENOVIEW® 3T Chest Coil with Philips' 3T MRI systems reinforces our shared goal of expanding the capabilities of MRI to deliver deeper clinical insights. Together, we're enabling clinicians to access advanced lung imaging tools that help improve diagnostic confidence and patient care."
The compatibility statement confirms that the FDA-cleared XENOVIEW 3T Chest Coil can be used with Philips MR 7700, Ingenia Elition X, and compatible software upgrade configurations from 2026 onwards. This development significantly expands the potential reach of Polarean's technology and supports its goal of making functional lung MRI more widely available to clinicians and patients worldwide.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.
Enquiries:
| Polarean Imaging plc | www.polarean.com/www.polarean-ir.com | |||||
| Christopher von Jako, Ph.D., Chief Executive Officer Charles Osborne, Chief Financial Officer | Via Walbrook PR | |||||
| Stifel (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | |||||
| Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good | ||||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 orpolarean@walbrookpr.com | |||||
| Anna Dunphy / Paul McManus / Marcus Ulker | Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082 | |||||